OOIR: Observatory of International Research

Papers

(The H4-Index of Archiv der Pharmazie is 30. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)

Article	Citations
Discovery of sulfadrug–pyrrole conjugates as carbonic anhydrase and acetylcholinesterase inhibitors	139
1,2,3‐Triazole hybrids as anticancer agents: A review	102
Coumarin‐containing hybrids and their antibacterial activities	67
Novel benzoic acid derivatives: Synthesis and biological evaluation as multitarget acetylcholinesterase and carbonic anhydrase inhibitors	65
Coumarin derivatives with anticancer activities: An update	63
Sulfonamides incorporating ketene N,S‐acetal bioisosteres as potent carbonic anhydrase and acetylcholinesterase inhibitors	61
1,2,3‐Triazole hybrids with anti‐HIV‐1 activity	61
Determination of the inhibition profiles of pyrazolyl–thiazole derivatives against aldose reductase and α‐glycosidase and molecular docking studies	57
Synthesis, characterization, biological evaluation, and in silico studies of novel 1,3‐diaryltriazene‐substituted sulfathiazole derivatives	57
Novel metabolic enzyme inhibitors designed through the molecular hybridization of thiazole and pyrazoline scaffolds	55
Synthesis, characterization, molecular docking, and biological activities of coumarin–1,2,3‐triazole‐acetamide hybrid derivatives	50
1,3,5‐Triazine: A versatile pharmacophore with diverse biological activities	48
Recent advances with alkaline phosphatase isoenzymes and their inhibitors	46
Design and discovery of new 1,2,4‐triazolo[4,3‐c]quinazolines as potential DNA intercalators and topoisomerase II inhibitors	45
Aromatase inhibitors: Role in postmenopausal breast cancer	43
Pharmacophore‐linked pyrazolo[3,4‐d]pyrimidines as EGFR‐TK inhibitors: Synthesis, anticancer evaluation, pharmacokinetics, and in silico mechanistic studies	43
Synthesis and antidiabetic evaluation of benzimidazole‐tethered 1,2,3‐triazoles	42
Design, synthesis, and biological activity of novel dithiocarbamate‐methylsulfonyl hybrids as carbonic anhydrase inhibitors	40
Novel 2‐cyanoacrylamido‐4,5,6,7‐tetrahydrobenzo[b]thiophene derivatives as potent anticancer agents	38
Design, synthesis, molecular docking, and anticancer evaluations of 1‐benzylquinazoline‐2,4(1H,3H)‐dione bearing different moieties as VEGFR‐2 inhibitors	36
Recent update on antibacterial and antifungal activity of quinoline scaffolds	36
Pyrazole–coumarin and pyrazole–quinoline chalcones as potential antitubercular agents	35
Toad venom: A comprehensive review of chemical constituents, anticancer activities, and mechanisms	34
Phthalazine‐based VEGFR‐2 inhibitors: Rationale, design, synthesis, in silico, ADMET profile, docking, and anticancer evaluations	34
5‐(4‐Methoxybenzylidene)thiazolidine‐2,4‐dione‐derived VEGFR‐2 inhibitors: Design, synthesis, molecular docking, and anticancer evaluations	33

Design, synthesis, molecular modeling, and antimicrobial potential of novel 3‐[(1H‐pyrazol‐3‐yl)imino]indolin‐2‐one derivatives as DNA gyrase inhibitors	33
Natural indole‐containing alkaloids and their antibacterial activities	32
Design, synthesis, molecular docking, anticancer evaluations, and in silico pharmacokinetic studies of novel 5‐[(4‐chloro/2,4‐dichloro)benzylidene]thiazolidine‐2,4‐dione derivatives as VEGFR‐2 inhibit	31
Synthesis and in vitro carbonic anhydrases and acetylcholinesterase inhibitory activities of novel imidazolinone‐based benzenesulfonamides	31
In vitro and in silico studies of fluorinated 2,3‐disubstituted thiazolidinone‐pyrazoles as potential α‐amylase inhibitors and antioxidant agents	30
Synthesis, antimicrobial evaluation, DNA gyrase inhibition, and in silico pharmacokinetic studies of novel quinoline derivatives	30